Ignite Creation Date:
2024-05-06 @ 5:39 PM
Last Modification Date:
2024-10-26 @ 2:33 PM
Study NCT ID:
NCT05385900
Status:
UNKNOWN
Last Update Posted:
2022-05-23
First Post:
2022-05-17
Brief Title:
Immune Combined Targeted and Chemotherapy in Perioperative Treatment of Locally Advanced Gastric Cancer
Sponsor:
Xijing Hospital
Organization:
Xijing Hospital
Study Overview
Official Title:
An Exploratory Study of Pembrolizumab Combined With Anlotinib and Chemotherapy Neoadjuvant Therapy of Locally Advanced Gastric Cancer
Status:
UNKNOWN
Status Verified Date:
2022-03
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ICTCPTLAGC
Brief Summary:
An exploratory study of pembrolizumab combined with anlotinib and chemotherapy in the perioperative treatment of locally advanced gastric cancer
Detailed Description:
Previous studies have shown that anti-vascular drugs have excellent anti-tumor effects in the neoadjuvant treatment of locally advanced gastric cancer The purpose of this study was to evaluate the neoadjuvant treatment of locally advanced gastric cancer with Penpulimab combined with anlotinib and chemotherapy pathological complete response rate disease-free survival objective response rate R0 resection rate and safety The subjects used in the study were patients with resectable or potentially resectable T34NM0 gastric cancer who were confirmed by endoscopic ultrasonography and enhanced CT The specific dosing schedule of Piamprimab combined with anlotinib and chemotherapy was adopted After receiving the corresponding neoadjuvant therapy for 3 cycles surgery should be performed within 3-6 weeks after drug withdrawal it is recommended that patients be given corresponding Adjuvant therapy the specific adjuvant therapy plan shall be formulated by the investigator according to the individual situation of the patient The primary endpoint was pathological complete response rate and secondary key indicators were disease-free survival objective response rate R0 resection rate and safety
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None